Citations

Institution: Mayo Clinic Clear

Showing 10 of 108083 citations.

World Endoscopy Organization's Response to the World Health Organization's Global Initiative on Artificial Intelligence for Health
Bhat, Purnima , Mushtaq, Junaid, Tajiri, Hisao, Mori, Yuichi, Bhat, Purnima , Coelho–Prabhu, Nayantara , Kalapala, Rakesh

Digestive Endoscopy | August 5, 2025 | Volume: 37 | Issue: 11 | Pages: 1143-1147

10.1111/den.70011 | PMID 40759486 Get It

ABSTRACT In response to the World Health Organization's (WHO) Global Initiative on Artificial Intelligence (AI) for Health, the World Endoscopy Organization (WEO) highlights the unique challenges and opportunities AI presents for gastrointestinal endoscopy, particularly in resource‐limited settings. While AI technologies have shown promise in improving diagnostic accuracy and efficiency in high‐resource environments, their implementation in low‐ and middle‐income countries is hindered by infrastructural, economic, regulatory, and training barriers. This commentary explores how these challenges may exacerbate existing healthcare disparities, emphasizing the need for localized datasets, affordable AI models, simplified regulatory frameworks, and workforce capacity building. The WEO supports WHO's call for equitable AI deployment and advocates for region‐specific solutions, including mobile and offline AI tools, public‐private partnerships, locally developed algorithms aligned with prevalent disease patterns, and a flexibly adapted regulatory framework. By leveraging WEO's training networks and fostering collaboration among governments, clinicians, and industry, the integration of AI into endoscopy can become more accessible and relevant to underserved populations. The commentary underscores that AI should not be seen as a luxury but as a tool to bridge global disparities in care quality. Ensuring responsible and inclusive AI integration requires both global coordination and context‐specific adaptations to truly benefit all healthcare systems.
Artificial Intelligence-Assisted Colonoscopy With or Without Mucosal Exposure Device for Detection of Colorectal Adenomas: A Meta-Analysis
Beran, Azizullah , Ramai, Daryl, Albakri, Almaza A., Spadaccini, Marco , Hassan, Cesare , Guardiola, John , Rex, Douglas K., Spadaccini, Marco , Hassan, Cesare , Guardiola, John J , Nayfeh, Tarek , Saleem, Nasir , Repici, Alessandro

Endoscopy International Open | August 4, 2025 | Volume: 13 | Issue: CP | Pages: No page available

10.1055/a-2676-4144 | PMID 40932819 Get It

Abstract Artificial intelligence (AI) and mucosal exposure devices like Endocuff have independently improved the adenoma detection rate (ADR) during colonoscopy. This meta-analysis evaluated the combined effect of Endocuff and AI versus AI alone on colorectal neoplasia detection rates. We searched PubMed, Embase, and Web of Science for randomized controlled trials (RCTs) comparing the impact of Endocuff+AI versus AI alone on colorectal neoplasia detection. Primary outcome was ADR; secondary outcomes included advanced adenoma detection rate (AADR), sessile serrated lesion detection rate (SSLDR), cecal intubation time, and withdrawal time. Pooled risk ratios (RRs) and mean differences (MDs) with 95% confidence intervals (CIs) were calculated using a random-effects model. Three RCTs with 2404 subjects were included (n = 1198 Endocuff+AI vs. n = 1206 AI alone). ADR was significantly higher in the Endocuff+AI group than in the AI alone group (54% vs. 48%, respectively) (RR 1.12, 95% CI 1.03–1.21, P = 0.01, I2 = 0%). There was a trend toward higher AADR (12.3% vs. 10%, RR 1.23, 95% CI 0.96–1.59, P = 0.10, I2 = 17%) and SSLDR (17.6% vs. 15.5%, RR 1.16, 95% CI 0.96–1.40, P = 0.13, I2 = 0%) in the Endocuff+AI group compared with the AI alone group, but it did not reach statistical significance. Both cecal intubation time (MD -0.61 minutes; 95% CI -1.54–0.33; P = 0.20; I2 = 87%) and withdrawal time (MD -0.42 minutes; 95% CI -1.01–0.17; P = 0.17, I2 = 60%) were similar between the two groups. Endocuff combined with AI was superior to AI alone in improving the adenoma detection rate without increasing intubation or withdrawal times.
ST8Sia6 overexpression protects pancreatic β cells from spontaneous autoimmune diabetes in nonobese diabetic mice
Choe, Justin, Belmonte, Paul , Crotts, Sydney B. , Zastrow, Alexi, Rajcula, Matthew, Hammer, Brady, Shapiro, Michael J. , Matveyenko, Aleksey V. , Matveyenko, Aleksey, Nguyen, Thanh , Friedman, David J. , Wilhelm, Claire, Shapiro, Michael J., Shapiro, Virginia Smith

Journal of Clinical Investigation | August 4, 2025 | Volume: 135 | Issue: 15 | Pages: No page available

10.1172/jci181207 | PMID 40759576 Get It

Type 1 diabetes is characterized by the autoimmune destruction of pancreatic β cells, resulting in permanent loss of glucose homeostasis. Islet transplantation is a promising potential cure that remains hindered by immune rejection. We previously showed that ST8Sia6 expression on tumors reduced immune surveillance and hypothesized that this sialyltransferase could protect β cells from autoimmune destruction. Here, we demonstrate that ectopic expression of ST8Sia6 in β cells of female nonobese diabetic mice (NOD βST) decreased the spontaneous incidence of diabetes by 90% and preserved β cell mass. NOD βST mice had comparable insulitis at 8 weeks of age that did not progress over time compared with littermate controls. β Cell–autoreactive B and T cells were present in NOD βST mice, indicating a peripheral rather than central mechanism of immune tolerance. The islets of NOD βST mice displayed a dampened type 1 immune response and reduced IL-12p35 expression in dendritic cells compared with those of littermate controls. The peripheral protection persisted even after removal of ST8Sia6 expression at 20 weeks of age, indicating that transient expression was sufficient for establishment of tolerance. These results demonstrate that ST8Sia6 protects β cells from immune-mediated attack and rejection, highlighting its therapeutic potential for autoimmune disorders.
Variables related to locoregional and distant recurrence in esophageal cancer
Fonseca, Stella , RAMOS, Igor Gabriel Silva , Maegawa, Felipe B. , Usón, Pedro Luiz Serrano , Tustumi, Francisco , Fonseca, Sarah , Maegawa, Felipe Antonio Boff , Uson, Pedro L S

ABCD. Arquivos Brasileiros de Cirurgia Digestiva (São Paulo) | August 4, 2025 | Volume: 38 | Issue: No issue available | Pages: No page available

10.1590/0102-67202025000020e1889 | PMID 40767665 Get It

ABSTRACT Background: Esophageal cancer remains one of the most aggressive malignancies of the gastrointestinal tract, with high rates of recurrence and mortality despite curative-intent surgery and adjuvant therapies. Identifying factors associated with recurrence is crucial for improving outcomes and guiding personalized treatment. Aims: The aim of this study was to evaluate pretreatment and treatment-related variables associated with recurrence in patients with esophageal cancer undergoing surgical resection. Methods: This retrospective study analyzed data from patients with stage I–III esophageal carcinoma who underwent esophagectomy between 2000 and 2025, using the Fundação Oncocentro de São Paulo (FOSP) database. Clinical, histological, and treatment-related variables were evaluated. Disease-free survival and recurrence patterns were assessed using Cox proportional hazards models and Fine–Gray subdistribution hazard models. Results: A total of 2,057 patients were included, with a mean follow-up of 36.5 months (±44.8). In the multivariate analysis, advanced tumor stage (stage II: HR 1.68, 95%CI 1.21–2.33; stage III: HR 3.23, 95%CI 2.29–4.56; both p<0.01), location (middle esophagus: HR 1.31, 95%CI 1.11–1.54; p=0.001; upper esophagus: HR 1.54, 95%CI 1.21–1.96; p<0.001), and histological subtype (rare histologies: HR 2.17, 95%CI 1.35–3.49; p=0.001) were associated with worse disease-free survival. Multimodal therapy improved disease-free survival (HR 0.40, 95%CI 0.24–0.66) in stage III tumors. Squamous cell carcinoma was independently associated with locoregional recurrence (SHR 1.52, 95%CI 1.05–2.20; p=0.027). For distant recurrence, squamous cell carcinoma showed a protective effect (SHR 0.52, 95%CI 0.31–0.88; p=0.015), while high tumor grade (grade II: SHR 3.65, 95%CI 1.98–6.72; p<0.001) was associated with an increased risk. Multimodal treatments influenced recurrence patterns but did not independently predict outcomes after adjustment. Conclusions: Tumor stage, location, and histology were strong predictors of disease-free survival after surgery for esophageal cancer. Histological subtypes significantly influenced recurrence patterns. Squamous cell carcinoma was associated with a higher risk of locoregional recurrence but a lower risk of distant metastasis compared to adenocarcinoma. Multimodal therapy demonstrated a protective effect in stage III disease.
VPS29C: Adding complexity to the Retromer complex
Chen, Baoyu , Billadeau, Daniel D. , Billadeau, Daniel D , Burstein, Ezra

Proceedings of the National Academy of Sciences | August 4, 2025 | Volume: 122 | Issue: 32 | Pages: No page available

10.1073/pnas.2515546122 | PMID 40758896 Get It

Cryptic intronic transcriptional initiation generates efficient endogenous mRNA templates for C9orf72-associated RAN translation
Miller, Shannon L. , Green, Katelyn M. , Crone, Bradley , Tank, Elizabeth M. H. , Krans, Amy, Jansen‐West, Karen , Wieland, Clare M. , Ji, Eric W., Petrucelli, Leonard , Barmada, Sami J. , Tank, Elizabeth M H , Jansen-West, Karen, Wieland, Clare M , Ji, Eric W , Barmada, Sami , Todd, Peter K , Switzenberg, Jessica A. , Boyle, Alan P.

Proceedings of the National Academy of Sciences | August 4, 2025 | Volume: 122 | Issue: 32 | Pages: No page available

10.1073/pnas.2507334122 | PMID 40758885 Get It

Intronic GGGGCC hexanucleotide repeat expansions in C9orf72 are the most common genetic cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). Despite its intronic location, this repeat avidly supports synthesis of pathogenic dipeptide repeat (DPR) proteins via repeat-associated non-AUG (RAN) translation. However, the template RNA species that undergoes RAN translation endogenously remains unclear. Using long-read based 5′ RNA ligase-mediated rapid amplification of cDNA ends (5′ Repeat-RLM-RACE), we identified C9orf72 transcripts initiating within intron 1 in a C9BAC mouse model, patient-derived iNeurons, and iNeuron-derived polysomes. These cryptic m 7 G-capped mRNAs are at least partially polyadenylated and are more abundant than transcripts derived from intron retention or circular intron lariats. In RAN translation reporter assays, intronic template transcripts–even those with short (32 nucleotide) leaders–exhibited robust expression compared to exon–intron and repeat-containing lariat reporters. To assess endogenous repeat-containing lariat RNA contributions to RAN translation, we enhanced endogenous lariat stability by knocking down the lariat debranching enzyme Dbr1. However, this modulation did not impact DPR production in patient-derived iNeurons. These findings identify cryptic, linear, m 7 G-capped intron-initiating C9orf72 mRNAs as an endogenous template for RAN translation and DPR production, with implications for disease pathogenesis and therapeutic development.
A Century After Jacobson v. Massachusetts: Public Health Ethical Perspectives of Large Language Models on Vaccination
Mugu, Vamshi , Kandimalla, Mahathi, Mugu, S. Ruthvik, Sharma, Kshipra

2025 IEEE International Symposium on Ethics in Engineering, Science, and Technology (ETHICS) | August 4, 2025 | Volume: No volume available | Issue: No issue available | Pages: 1-4

10.1109/ethics65148.2025.11098289 Get It

Prehospital Workplace Violence (WPV) Dispatch Alerts: Anticipating Behavior and Preventing Violence
Arms, Kathryn J., Reiter, David T., Liedl, Chad P., Phillips, Jeffrey P., Clements, Casey M. , McGuire, Sarayna S. , Reiter, David T., Mullan, Aidan F.

Prehospital Emergency Care | August 4, 2025 | Volume: 30 | Issue: 5 | Pages: 630-638

10.1080/10903127.2025.2542536 | PMID 40758828 Get It

Monitoring cardiogenic shock: echodynamics vs. pulmonary artery catheter Viewpoints from two leading experts
Boretto, Paolo , Jentzer, Jacob C. , Frea, Simone , Pöss, Janine, Jentzer, Jacob C , Frea, Simone , Galluzzo, Alessandro

European Heart Journal: Acute Cardiovascular Care | August 4, 2025 | Volume: 14 | Issue: 9 | Pages: 576-578

10.1093/ehjacc/zuaf100 | PMID 40758819 Get It

Tumour-infiltrating lymphocyte therapy landscape: prospects and challenges
Chen, Ruqin , Roudkoli, Ali Rezazadeh , Dudek, Arkadiusz Z. , Johnson, Jeffrey , Rezazadeh, Ali , Dudek, Arkadiusz Z

BMJ Oncology | August 4, 2025 | Volume: 4 | Issue: 1 | Pages: e000566

10.1136/bmjonc-2024-000566 | PMID 40765841 Get It

Tumour-infiltrating lymphocyte (TIL) therapy has emerged as a promising adoptive cell transfer strategy for solid tumours. The recent accelerated approval of lifileucel by the Food and Drug Administration marks a significant milestone in the clinical application of TIL therapy. This review comprehensively examines the historical development, biology, clinical efficacy, safety and limitations of TIL therapy. We explore advancements in TIL manufacturing, including novel culture techniques, genetic modifications and automation, to enhance scalability and effectiveness. Despite promising results, TIL therapy faces challenges such as high-dose interleukin-2 toxicity, complex manufacturing processes and immune evasion mechanisms. Emerging strategies, including checkpoint inhibitor combinations, engineered TIL constructs and metabolic reprogramming, aim to improve TIL therapeutic efficacy. This review provides insights into the evolving landscape of TIL therapy and its potential to enhance current cancer immunotherapy.